Search
Patexia Research
Case number 1:21-cv-01293

Supernus Pharmaceuticals, Inc. v. Lupin Limited et al > Documents

Date Field Doc. No.Description (Pages)
May 18, 2023 119 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) (Topics 1-5) and Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Responses to Plaintiff's Third Set of Interrogatories (No. 11) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 05/18/2023) (2)
May 16, 2023 118 NOTICE of Change of Address by David A. Bilson (Bilson, David) (Entered: 05/16/2023) (1)
May 12, 2023 117 [SEALED] SO ORDERED re 115 Stipulation and Order to Amend Scheduling Order (Set/Reset Scheduling Order Deadlines - Fact Discovery completed by 10/13/2023. Opening Expert Reports due by 11/10/2023. Rebuttal Expert Reports due by 12/12/2023. Reply Expert Reports due by 1/12/2024. Expert Discovery due by 2/9/2024. A Pretrial Conference is set for 3/12/2024 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 3/18/2024 at 08:30 AM in Courtroom 4A before Judge Maryellen Noreika). Signed by Judge Maryellen Noreika on 5/12/2023. This order has been emailed to local counsel. (dlw) (Entered: 05/12/2023) (0)
May 11, 2023 115 [SEALED] STIPULATION and Proposed Order to Amend Scheduling Order by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Certificate of Service)(DiGiovanni, Francis) (Entered: 05/11/2023) (0)
May 11, 2023 116 REDACTED VERSION of 115 Stipulation by Supernus Pharmaceuticals, Inc. (DiGiovanni, Francis) Modified on 5/12/2023 (dlw). (Entered: 05/11/2023) (3)
Apr 18, 2023 114 NOTICE OF SERVICE of Supernus's Supplemental Notice of Depositions of Defendants Under Fed. R. Civ. P. 30(b)(6); Supernus's Third Set of Interrogatories (No. 11) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 04/18/2023) (2)
Apr 17, 2023 113 NOTICE requesting Clerk to remove Andrew M. Morrell as co-counsel. Reason for request: no longer affiliated with the case. (Bilson, David) (Entered: 04/17/2023) (1)
Apr 5, 2023 112 MEMORANDUM ORDER REGARDING CLAIM CONSTRUCTION. Signed by Judge Maryellen Noreika on 4/5/2023. (dlw) (Entered: 04/05/2023) (9)
Feb 22, 2023 111 Official Transcript of Markman held on 1.11.23 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale Hawkings,Email: dale_hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/15/2023. Redacted Transcript Deadline set for 3/27/2023. Release of Transcript Restriction set for 5/23/2023. (Rolfe, Michele) Modified on 2/22/2023 (dlw). (Entered: 02/22/2023) (58)
Feb 13, 2023 110 SEALED SO ORDERED re 108 STIPULATION and Order to Amend Scheduling Order (Set/Reset Scheduling Order Deadlines: Fact Discovery completed by 5/18/2023. Opening Expert Reports due by 6/8/2023. Rebuttal Expert Reports due by 7/17/2023. Reply Expert Reports due by 8/14/2023. Expert Discovery due by 9/5/2023. A Pretrial Conference is set for 1/11/2024 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 1/22/2024 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika). Signed by Judge Maryellen Noreika on 2/13/2023. (dlw) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (0)
Feb 9, 2023 108 [SEALED] STIPULATION TO EXTEND TIME to Amend Scheduling Order to various dates - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 02/09/2023) (0)
Feb 9, 2023 109 REDACTED VERSION of 108 STIPULATION TO EXTEND TIME to Amend Scheduling Order to various dates by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 02/09/2023) (3)
Feb 3, 2023 107 Joint STIPULATION TO EXTEND TIME for filing Expert Reports to various dates - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Phillips, John) (Entered: 02/03/2023) (2)
Jan 9, 2023 105 NOTICE OF SERVICE of Supernus's Responses to Defendants' Final Invalidity Contentions filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 01/09/2023) (2)
Jan 9, 2023 106 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [HIGHLY CONFIDENTIAL] Supplemental Non-Infringement Contentions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 01/09/2023) (2)
Jan 6, 2023 104 MOTION for Pro Hac Vice Appearance of Attorney Jason A. Kanter and Camille Y. Turner - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 01/06/2023) (4)
Jan 5, 2023 103 NOTICE OF SERVICE of Supernus's Responses and Objections to Defendants' Notice of Deposition to Supernus Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Supernus Pharmaceuticals, Inc..(Rahmeier, Thatcher) (Entered: 01/05/2023) (2)
Jan 4, 2023 102 MOTION for Pro Hac Vice Appearance of Attorney Payson LeMeilleur - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Certification of Payson LeMeilleur)(Bilson, David) (Entered: 01/04/2023) (Main Document) (2)
Jan 4, 2023 102 MOTION for Pro Hac Vice Appearance of Attorney Payson LeMeilleur - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Certification of Payson LeMeilleur)(Bilson, David) (Entered: 01/04/2023) (Certification of Payson LeMeilleur) (1)
Jan 3, 2023 99 SO ORDERED re 90 Joint Stipulation and Order (reducing claims and defenses). Signed by Judge Maryellen Noreika on 1/3/2023. (dlw) (Entered: 01/03/2023) (4)
Jan 3, 2023 100 ORAL ORDER re 96 Letter - IT IS HEREBY ORDERED that the Court is setting aside one (1) hour for the claim construction hearing with the time split equally between the parties. Any slide presentations the parties wish to use during the hearing shall be emailed (in PDF format) to MN_civil@ded.uscourts.gov no later than 24 hours prior to the hearing with hard copies delivered to the clerk's office within one (1) hour thereafter. The parties may, however, agree upon a different time to exchange their respective slides. ORDERED by Judge Maryellen Noreika on 1/3/2023. (dlw) (Entered: 01/03/2023) (0)
Jan 3, 2023 101 NOTICE to Take Deposition of Rajiv Khurana on January 13, 2023 filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 01/03/2023) (2)
Dec 30, 2022 97 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [HIGHLY CONFIDENTIAL] Final Invalidity Contentions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 12/30/2022) (2)
Dec 30, 2022 98 NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Supplemental Final Infringement Contentions filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 12/30/2022) (2)
Dec 28, 2022 92 SECOND AMENDED JOINT CLAIM Construction Chart by Supernus Pharmaceuticals, Inc. (DiGiovanni, Francis) Modified on 1/3/2023 (dlw). (Entered: 12/28/2022) (9)
Dec 28, 2022 93 Letter to The Honorable Maryellen Noreika from John C. Phillips, Jr. regarding Defendants' Technology Tutorial. (Phillips, John) (Entered: 12/28/2022) (1)
Dec 28, 2022 94 JOINT CLAIM CONSTRUCTION BRIEF filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 12/28/2022) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Main Document) (4)
Dec 28, 2022 96 Letter to Hon. Judge Maryellen Norieka from Francis DiGiovanni regarding Jan. 11, 2023 hearing on claim construction. (DiGiovanni, Francis) (Entered: 12/28/2022) (1)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit A) (23)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit B) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit C) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit D) (12)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit E) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit F) (23)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit G) (24)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit H) (10)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit I) (3)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit J) (24)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit K) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit L) (6)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit M) (10)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit N) (10)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit O) (8)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit P) (8)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit Q) (7)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit R) (7)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit S) (6)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit T) (7)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit U) (6)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit V) (7)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit W) (6)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit X) (5)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit Y) (8)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit Z) (30)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit AA) (25)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit BB) (8)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit CC) (8)
Dec 28, 2022 95 Joint APPENDIX re 94 Joint Claim Construction Brief by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W, # 24 Exhibit X, # 25 Exhibit Y, # 26 Exhibit Z, # 27 Exhibit AA, # 28 Exhibit BB, # 29 Exhibit CC, # 30 Exhibit DD)(DiGiovanni, Francis) (Entered: 12/28/2022) (Exhibit DD) (4)
Dec 27, 2022 91 Joint STIPULATION and Proposed Order to Extend Time to file the Parties' Joint Claim Construction Brief and accompanying Joint Appendix to and through December 28, 2022 re SO ORDERED,, Set/Reset Deadlines for Claim Construction Briefing, by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 12/27/2022) (3)
Dec 23, 2022 90 Joint STIPULATION and Order (reducing claims and defenses) by Supernus Pharmaceuticals, Inc. (DiGiovanni, Francis) Modified on 1/3/2023 (dlw). (Entered: 12/23/2022) (4)
Dec 20, 2022 89 STIPULATION TO EXTEND TIME to file the Parties' Joint Claim Construction Brief to December 27, 2022 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 12/20/2022) (3)
Dec 16, 2022 88 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [HIGHLY CONFIDENTIAL] Sur-Reply Claim Construction Brief, the [HIGHLY CONFIDENTIAL] Expert Declaration of Graham Buckton, Ph.D., D.Sc. in Support of Defendants' Sur-Reply Claim Construction Brief, and the [HIGHLY CONFIDENTIAL] Declaration of Jeremiah S. Helm filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 12/16/2022) (2)
Nov 28, 2022 87 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Supplemental Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 11/28/2022) (2)
Nov 18, 2022 86 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Answering Claim Construction Brief, Declaration of Graham Buckton, Ph.D., D.Sc. in Support of Defendants' Responsive Claim Construction Brief and Declaration of Inzer C. Ni filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 11/18/2022) (2)
Nov 10, 2022 85 STIPULATION TO EXTEND TIME Fact discovery cut-off and certain scheduling order deadlines to January 20, 2023 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 11/10/2022) (2)
Nov 9, 2022 84 REDACTED VERSION of 78 Letter, by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit Exs. A-G)(DiGiovanni, Francis) (Entered: 11/09/2022) (Main Document) (8)
Nov 9, 2022 84 REDACTED VERSION of 78 Letter, by Supernus Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit Exs. A-G)(DiGiovanni, Francis) (Entered: 11/09/2022) (Exhibit Exs. A-G) (30)
Nov 8, 2022 82 REDACTED VERSION of 79 Letter by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Phillips, John) (Entered: 11/08/2022) (Main Document) (7)
Nov 8, 2022 83 SO ORDERED, re: D.I. 81 Stipulation to Extend Time. Signed by Judge Mary Pat Thynge on 11/8/2022. (DAT) (Entered: 11/08/2022) (2)
Nov 8, 2022 82 REDACTED VERSION of 79 Letter by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Phillips, John) (Entered: 11/08/2022) (Exhibits 1-4) (23)
Nov 8, 2022 82 REDACTED VERSION of 79 Letter by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Phillips, John) (Entered: 11/08/2022) (Certificate of Service) (1)
Nov 7, 2022 81 STIPULATION TO EXTEND TIME for Plaintiff to file a redacted public version of its [Sealed] Opening Letter Brief in Support of its Motion to Compel and accompanying exhibits (D.I. 78) to November 9, 2022 - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Bilson, David) (Entered: 11/07/2022) (2)
Nov 4, 2022 80 ORAL ORDER granting in part and denying in part 73 MOTION For Discovery Conference. The transcript of the November 3, 2022 discovery dispute teleconference shall serve as the ORDER of the court. In accordance with the rulings made on the record: IT IS HEREBY ORDERED that Supernus's motion is GRANTED-IN-PART and DENIED-IN-PART, specifically, no later than November 28, 2022: (1) Lupin shall identify any additional ESI custodians who are most likely to have discoverable information relevant to ANDA215561, see D.I. 78-3, Ex. C at 2, and shall supplement its written disclosures; (2) Lupin shall re-run its ESI searches and shall produce all internal communications concerning Lupin's ANDA and ANDA products, D.I. 78 at 3; (3) With respect to documents and communications discussing Lupins strategy for responding to the FDAs Complete Response Letter (CRL) of April 18, 2022, D.I. 79 at 1, Lupin shall either produce these documents or shall assemble a privilege log describing each withheld document and its specific privilege claim as to each one; and (4) the parties shall meet and confer to propose any modifications to the case schedule necessary to complete fact discovery within the confines of the Scheduling Order at D.I. 19 . As to Supernus's other motions in Sections II and III of its letter brief at D.I. 78 at 3-4, these motions are DENIED. Ordered by Judge Mary Pat Thynge on 11/3/2022. (DAT) (Entered: 11/04/2022) (0)
Nov 1, 2022 79 [SEALED] Letter to The Honorable Mary Pat Thynge from John C. Phillips, Jr. regarding Answering Letter Brief in Opposition to Plaintiff's Motion to Compel. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Phillips, John) (Entered: 11/01/2022) (0)
Oct 31, 2022 78 [SEALED] Letter to Chief U.S. Magistrate Judge Mary Pat Thynge from Thatcher A. Rahmeier regarding Supernus's Opening Letter Brief in Support of Motion to Compel (D.I. 73) - re 73 MOTION For Discovery Conference . (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Rahmeier, Thatcher) (Main Document 78 replaced on 10/31/2022) (DAT). (Entered: 10/31/2022) (0)
Oct 25, 2022 77 CLAIM Construction Chart by Supernus Pharmaceuticals, Inc.. (Rahmeier, Thatcher) (Entered: 10/25/2022) (18)
Oct 24, 2022 75 STIPULATION TO EXTEND TIME to File an Amended Joint Claim Construction Chart to October 25, 2022 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 10/24/2022) (2)
Oct 24, 2022 76 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 7-10) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 10/24/2022) (2)
Oct 21, 2022 74 STIPULATION to Extend Time re 67 Order,, by Lupin Atlantis Holdings S.A., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Bilson, David) (Entered: 10/21/2022) (2)
Oct 18, 2022 73 MOTION For Discovery Conference - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 10/18/2022) (2)
Oct 17, 2022 72 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Responses to Plaintiff's Amended First Set of Requests for Admission (Nos. 1-46) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 10/17/2022) (2)
Oct 14, 2022 71 NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Supplemental Responses and Objections to Defendants' First Set of Interrogatories (Nos. 3, 4, 9-12) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 10/14/2022) (3)
Oct 13, 2022 69 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Amended First Set of Requests for Admissions (Nos. 1-50) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 10/13/2022) (2)
Oct 13, 2022 70 ORAL ORDER - Consistent with the Scheduling Order, the parties' contacted chambers to request a teleconference date for a discovery dispute. IT IS HEREBY ORDERED that the dispute is referred to Judge Mary Pat Thynge. The parties are directed to review Judge Thynge's Discovery Dispute Procedures Order located at: https://www.ded.uscourts.gov/judge/chief-magistrate-judge-mary-pat-thynge, forms. ORDERED by Judge Maryellen Noreika on 10/13/2022. (dlw) (Entered: 10/13/2022) (0)
Oct 12, 2022 68 NOTICE OF SERVICE of Supernus's Amended First Set of Requests for Admission (Nos. 1-46) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 10/12/2022) (2)
Oct 4, 2022 67 ORDER re 66 Joint Claim Construction Chart - IT IS HEREBY ORDERED that: 1. The parties have identified nine (9) disputed terms, which seems high for an ANDA case. The parties shall meet and confer to see if they can resolve or narrow their disputes. 2. As to disputed footnote 1, the Court will address attempts to assert additional patents if they arise. 3. On or before October 21, 2022, the parties shall file an Amended Joint Claim Construction Chart setting forth the narrowed or resolved disputes or shall file a letter stating that no agreements have been reached. Signed by Judge Maryellen Noreika on 10/4/2022. (dlw) (Entered: 10/04/2022) (1)
Sep 30, 2022 57 NOTICE to Take Deposition of Hua Wang (Amended) on October 24, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 58 NOTICE to Take Deposition of Argaw Kidane (Amended) on October 17, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 59 NOTICE to Take Deposition of Todd Horich (Amended) on November 2, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 60 NOTICE to Take Deposition of Tami Martin (Amended) on November 4, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 61 NOTICE to Take Deposition of Padmanabh P. Bhatt (Amended) on October 28, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 62 NOTICE to Take Deposition of Michael L. Vieira (Amended) on October 19, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 63 NOTICE to Take Deposition of Likan Liang (Amended) on November 8, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Phillips, John) (Entered: 09/30/2022) (2)
Sep 30, 2022 64 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Invalidity Contentions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/30/2022) (2)
Sep 30, 2022 65 NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Final Infringement Contentions filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/30/2022) (2)
Sep 30, 2022 66 Joint CLAIM Construction Chart by Supernus Pharmaceuticals, Inc. (DiGiovanni, Francis) Modified on 10/3/2022 (dlw). (Entered: 09/30/2022) (19)
Sep 27, 2022 56 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s First Set of Requests for Admissions (Nos. 1-65) and Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Second Set of Interrogatories (Nos. 13-15) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/27/2022) (2)
Sep 23, 2022 55 NOTICE OF SERVICE of Supernus's Second Set of Interrogatories (Nos. 7-10) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/23/2022) (2)
Sep 22, 2022 53 STIPULATION TO EXTEND TIME of Certain Scheduling Order Deadlines to Fact Discovery cut-off: 11/9/2022; Supplementation of Infringement and Invalidity Contentions: 9/30/2022; Final Non-Infringement Contentions and Final Validity Contentions: 11/14/2022 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis) (Entered: 09/22/2022) (2)
Sep 22, 2022 54 NOTICE OF SERVICE of Notices of Deposition of Pramod Dahibhate, Makrand Avachat, and Jason Genburger filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/22/2022) (2)
Sep 21, 2022 44 NOTICE to Take Deposition of Padmanabh P. Bhatt on October 17, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 45 NOTICE to Take Deposition of Plaintiff Under Federal Rule of Civil Procedure 30(b)(6) on October 25, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (9)
Sep 21, 2022 46 NOTICE to Take Deposition of Hua Wang on October 14, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 47 NOTICE to Take Deposition of Argaw Kidane on October 7, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 48 NOTICE to Take Deposition of Michael L. Vieira on October 10, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 49 NOTICE to Take Deposition of Likan Liang on October 19, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 50 NOTICE to Take Deposition of Todd Horich on October 18, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 51 NOTICE to Take Deposition of Tami Martin on October 12, 2022 filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 21, 2022 52 NOTICE OF SERVICE of Defendants Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) (Topics 1-27) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/21/2022) (2)
Sep 16, 2022 42 NOTICE OF SERVICE of Plaintiff's Proposed Claim Constructions and Responsive Intrinsic Evidence filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/16/2022) (2)
Sep 16, 2022 43 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Second Disclosure of Proposed Intrinsic Evidence in Support of Their Proposed Constructions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/16/2022) (2)
Sep 15, 2022 41 NOTICE OF SERVICE of Supernus's First Set of Requests for Admission (Nos. 1-78) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/15/2022) (2)
Sep 9, 2022 38 MOTION for Pro Hac Vice Appearance of Attorney Inzer C. Ni - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Certification of Inzer C. Ni)(Bilson, David) (Entered: 09/09/2022) (Main Document) (2)
Sep 9, 2022 39 NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Initial Disclosure of Proposed Intrinsic Evidence in Support of Their Proposed Constructions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David) (Entered: 09/09/2022) (2)
Sep 9, 2022 40 NOTICE OF SERVICE of Plaintiff's Preliminary Claim Constructions and Supporting Intrinsic Evidence filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/09/2022) (2)
Sep 9, 2022 38 MOTION for Pro Hac Vice Appearance of Attorney Inzer C. Ni - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # 1 Certification of Inzer C. Ni)(Bilson, David) (Entered: 09/09/2022) (Certification of Inzer C. Ni) (1)
Sep 6, 2022 37 NOTICE OF SERVICE of Supernus's Notice of Depositions of Defendants Under Federal Rule of Civil Procedure 30(b)(6) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis) (Entered: 09/06/2022) (2)
Jul 29, 2022 36 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Initial Disclosure of Proposed Claim Constructions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Jul 1, 2022 35 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.s Initial Disclosure of Proposed Claim Terms for Construction filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Jun 27, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Jeremiah S. Helm for Lupin Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
Jun 24, 2022 N/A Order (0)
Docket Text: SO ORDERED re [34] MOTION for Pro Hac Vice Appearance of Attorney Jeremiah S. Helm, Ph.D. Ordered by Judge Maryellen Noreika on 6/24/2022. (asw)
Jun 24, 2022 34 Main Document (2)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jeremiah S. Helm, Ph.D. - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # (1) Certification of Jeremiah S. Helm, Ph.D.)(Bilson, David)
Jun 24, 2022 34 Certification of Jeremiah S. Helm, Ph.D. (1)
Jun 15, 2022 33 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Initial Invalidity Contentions filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Apr 27, 2022 32 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Paragraph 4(c) Initial Claim Chart and Appendix 1 filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Apr 18, 2022 31 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1-12) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Mar 30, 2022 30 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Plaintiff Supernus Pharmaceuticals, Inc.'s Identification of Accused Products and Asserted Patents filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Mar 28, 2022 28 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Reponses to Plaintiff's First Set of Interrogatories (Nos. 1-6) and Defendants Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s [CONFIDENTIAL] Objections and Responses to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-61) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Mar 28, 2022 29 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Responses and Objections to Defendants' First Set of Requests for Production of Documents and Things (Nos. 1-108) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Mar 16, 2022 27 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s First Set of Interrogatories (Nos. 1-12) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Mar 9, 2022 25 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Supernus's Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Mar 9, 2022 26 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Defendants Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Mar 8, 2022 24 Protective Order (20)
Docket Text: PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 3/8/2022. (dlw)
Mar 7, 2022 N/A CORRECTING ENTRY: (0)
Docket Text: CORRECTING ENTRY: D.I. 23 has been deleted from the docket and will be re-filed using the proper event code. (dlw)
Mar 7, 2022 23 Stipulation (20)
Docket Text: STIPULATION for Entry of Protective Order by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis)
Mar 3, 2022 N/A SO ORDERED (0)
Docket Text: SO ORDERED re [22] STIPULATION TO EXTEND TIME to Apply for a Protective Order to March 8, 2022 filed by Supernus Pharmaceuticals, Inc. ORDERED by Judge Maryellen Noreika on 3/3/2022. (dlw)
Mar 2, 2022 22 Stipulation to EXTEND Time (2)
Docket Text: STIPULATION TO EXTEND TIME to Apply for a Protective Order to March 8, 2022 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis)
Feb 25, 2022 N/A SO ORDERED (0)
Docket Text: SO ORDERED re [20] STIPULATION TO EXTEND TIME to Apply for a Protective Order to March 2, 2022. ORDERED by Judge Maryellen Noreika on 2/25/2022. (dlw)
Feb 25, 2022 18 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Lupin Limited, Lupin Atlantis Holdings, S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s First Set of Requests for Production of Documents and Things (Nos. 1-108) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Feb 25, 2022 19 Scheduling Order (12)
Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 9/16/2022. Amended Pleadings due by 9/16/2022. Fact Discovery completed by 10/26/2022. Opening Expert Reports due by 2/8/2023. Rebuttal Expert Reports due by 3/17/2023. Reply Expert Reports due by 4/14/2023. Expert Discovery due by 5/5/2023. Claim Construction Opening Brief served by 11/4/2022. Claim Construction Answering Brief served by 11/18/2022. Claim Construction Reply Brief served by 12/2/2022. Claim Construction Surreply Brief served by 12/16/2022. Joint Claim Construction Brief filed by 12/21/2022. A Markman Hearing is set for 1/11/2023 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 6/13/2023 at 11:00 AM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 6/20/2023 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 2/25/2022. (dlw)
Feb 25, 2022 20 Stipulation to EXTEND Time (2)
Docket Text: STIPULATION TO EXTEND TIME to Apply for a Protective Order to March 2, 2022 - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis)
Feb 25, 2022 21 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Requests for Production and Plaintiff's First Set of Interrogatories filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Feb 23, 2022 16 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Defendants Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc. and Lupin Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V..(Bilson, David)
Feb 23, 2022 17 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Supernus Pharmaceuticals, Inc.'s Initial Disclosures under Fed. R. Civ. P. 26(a)(1) filed by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Feb 18, 2022 15 Main Document (1)
Docket Text: Letter to The Honorable Maryellen Noreika from Francis DiGiovanni regarding Revised Proposed Scheduling Order - re [14] Oral Order,,,. (Attachments: # (1) Exhibit A)(DiGiovanni, Francis) (Attachment 1 replaced on 2/25/2022) (dlw).
Feb 18, 2022 15 Exhibit A (12)
Feb 11, 2022 N/A Oral Order (0)
Docket Text: ORAL ORDER re [13] Letter and Proposed Scheduling Order - Having reviewed the parties' letter and proposed Scheduling Order, IT IS HEREBY ORDERED that for any witness likely to be called live at trial, that witness will appear and testify live in the United States for their deposition. For other witnesses, the parties should work together in a constructive and cooperative manner to determine a reasonable location and the logistics for such depositions. IT IS HEREBY FURTHER ORDERED that, if the parties expect the Court to decide the matter prior to the expiration of the 30-month stay, the trial will begin on June 20, 2023. IT IS FINALLY ORDERED that, on or before 2/18/2022, the parties shall submit a revised Proposed Scheduling Order. ORDERED by Judge Maryellen Noreika on 2/11/2022. (dlw)
Feb 10, 2022 13 Main Document (2)
Docket Text: Letter to The Honorable Maryellen Noreika from Francis DiGiovanni regarding Proposed Scheduling Order - re [12] Oral Order. (Attachments: # (1) Exhibit A)(DiGiovanni, Francis) Modified on 2/11/2022 (dlw).
Feb 10, 2022 13 Exhibit A (14)
Jan 11, 2022 N/A Oral Order (0)
Docket Text: ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 1/11/2022. (dlw)
Jan 10, 2022 11 Answer to Counterclaim (24)
Docket Text: ANSWER to [8] Answer to Complaint,, Counterclaim, by Supernus Pharmaceuticals, Inc..(DiGiovanni, Francis)
Dec 22, 2021 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Carol M. Pitzel Cruz for Lupin Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (smg)
Dec 21, 2021 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney William R. Zimmerman, Andrew E. Morrell for Lupin Atlantis Holdings S.A., for Lupin Inc., for Lupin Limited, for Lupin Pharmaceuticals, Inc., for Nanomi B.V. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr)
Dec 20, 2021 N/A SO ORDERED (0)
Docket Text: SO ORDERED re [10] MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Carol Pitzel Cruz and Andrew E. Morrell, Ph.D. - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V. ORDERED by Judge Maryellen Noreika on 12/20/2021. (dlw)
Dec 20, 2021 8 Answer to Complaint (30)
Docket Text: ANSWER to [1] Complaint, Affirmative Defenses, COUNTERCLAIM against Supernus Pharmaceuticals, Inc. by Nanomi B.V., Lupin Pharmaceuticals, Inc., Lupin Limited, Lupin Inc., Lupin Atlantis Holdings S.A. (Phillips, John) Modified on 12/20/2021 (dlw).
Dec 20, 2021 9 Disclosure Statement (2)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Ltd. for Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Pharmaceuticals, Inc., Nanomi B.V. filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Phillips, John)
Dec 20, 2021 10 Main Document (2)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Carol Pitzel Cruz and Andrew E. Morrell, Ph.D. - filed by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., Nanomi B.V.. (Attachments: # (1) Certification of William R. Zimmerman, # (2) Certification of Carol Pitzel Cruz, # (3) Certification of Andrew E. Morrell, Ph.D.)(Bilson, David)
Dec 20, 2021 10 Certification of William R. Zimmerman (1)
Dec 20, 2021 10 Certification of Carol Pitzel Cruz (1)
Dec 20, 2021 10 Certification of Andrew E. Morrell, Ph.D. (1)
Sep 27, 2021 7 Main Document (2)
Docket Text: NOTICE of Waiver of Summons by Supernus Pharmaceuticals, Inc. (Attachments: # (1) Exhibit A)(DiGiovanni, Francis)
Sep 27, 2021 7 Exhibit A (5)
Sep 17, 2021 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Edgar H. Haug, Richard F. Kurz, and Nicholas F. Giove for Supernus Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
Sep 16, 2021 N/A SO ORDERED (0)
Docket Text: SO ORDERED re [6] MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug, Nicholas F. Giove, Richard F. Kurz filed by Supernus Pharmaceuticals, Inc. ORDERED by Judge Maryellen Noreika on 9/16/2021. (dlw)
Sep 15, 2021 N/A Case Assigned/Reassigned (0)
Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb)
Sep 13, 2021 6 Motion for Leave to Appear Pro Hac Vice (5)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Edgar H. Haug, Nicholas F. Giove, Richard F. Kurz - filed by Supernus Pharmaceuticals, Inc.. (DiGiovanni, Francis)
Sep 10, 2021 N/A No Summons Issued (0)
Docket Text: No Summons Issued. (srs)
Sep 10, 2021 1 Main Document (36)
Docket Text: COMPLAINT filed against Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc., and Nanomi B.V. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3696566.) - filed by Supernus Pharmaceuticals, Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit, # (11) Civil Cover Sheet)(srs)
Sep 10, 2021 1 Exhibit A (24)
Sep 10, 2021 1 Exhibit B (23)
Sep 10, 2021 1 Exhibit C (22)
Sep 10, 2021 1 Exhibit D (22)
Sep 10, 2021 1 Exhibit E (23)
Sep 10, 2021 1 Exhibit F (23)
Sep 10, 2021 1 Exhibit G (23)
Sep 10, 2021 1 Exhibit H (22)
Sep 10, 2021 1 Exhibit I (24)
Sep 10, 2021 1 Exhibit (23)
Sep 10, 2021 1 Civil Cover Sheet (3)
Sep 10, 2021 2 Magistrate Consent Forms (3)
Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs)
Sep 10, 2021 3 ANDA Form (1)
Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/30/2021. Date of Expiration of Patent: 11/16/2027 for all patents except 8,298,576 4/4/2028.Thirty Month Stay Deadline: 1/30/2024. (srs)
Sep 10, 2021 4 Patent/Trademark Report to Commissioner (2)
Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,298,576 ; 8,298,580 ; 8,663,683 ; 8,877,248 ; 8,889,191 ; 8,992,989 ; 9,549,940 ; 9,555,004 ; 9,622,983 ; 10,314,790 . (srs)
Sep 10, 2021 5 Disclosure Statement (2)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent The Vanguard Group, Inc., and Corporate Parent BlackRock Institutional Trust Company for Supernus Pharmaceuticals, Inc. filed by Supernus Pharmaceuticals, Inc. (srs)
Sep 10, 2021 1 Complaint* (1)
Menu